Literature DB >> 1349074

Serum and faecal tumour necrosis factor-alpha as marker of intestinal inflammation.

G A Lanfranchi, A Tragnone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1349074     DOI： 10.1016/0140-6736(92)90573-l

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase.

Authors:  Mark W Musch; Lane L Clarke; Daniel Mamah; Lara R Gawenis; Zheng Zhang; William Ellsworth; David Shalowitz; Navdha Mittal; Petros Efthimiou; Ziad Alnadjim; Steve D Hurst; Eugene B Chang; Terrence A Barrett
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn's Disease.

Authors:  Sundaram G Veerappan; Martin Healy; Bernard J Walsh; Colm A O'Morain; Jacqueline S Daly; Barbara M Ryan
Journal:  Dig Dis Sci       Date:  2015-03-03       Impact factor: 3.199

3.  Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.

Authors:  Marina Mauro; Vladimir Radovic; David Armstrong
Journal:  Can J Gastroenterol       Date:  2007-10       Impact factor: 3.522

4.  MHC II-PI3K/Akt/mTOR Signaling Pathway Regulates Intestinal Immune Response Induced by Soy Glycinin in Hybrid Grouper: Protective Effects of Sodium Butyrate.

Authors:  Bin Yin; Hongyu Liu; Beiping Tan; Xiaohui Dong; Shuyan Chi; Qihui Yang; Shuang Zhang
Journal:  Front Immunol       Date:  2021-01-18       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.